Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Atypical Hyperplasia · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · Endometrial Carcinoma
Primary: Change in Tumor Proliferation — -0.17 percent (represented by mean) of cells
Phase 2 N=10 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
Early Phase 1 N=100 Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion
Endometrial Cancer
Primary: Percentage of Participants With Positive Predictive Value and Negative Predictive Value From Fluorescein Visualization — 71; 100; 85; 90 percentage of participants
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Phase 2 N=53 A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Solid Tumors and Advanced Endometrial Cancer · Endometrial Cancer · Second-line Treatment
Primary: Progression Free Survival (PFS) Rate — 31.8; 29.0 Percentage of participants
N/A N=50 Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer
Endometrial Cancer · Chemotherapy Effect · Quality of Life
Primary: The Impact in Terms of Overall Quality of Life of Adjuvant Chemotherapy by the QLQ-C30 Questionnaire — 61.7; 71.1 units on a scale
Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Phase 2 N=70 BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Advanced Endometrial Cancer
Primary: Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status — 49; 21; 70; 1 number of participants
Phase 2 N=21 Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Participant Responses — 2; 8; 4; 6 participants
N/A N=118 Endometrial Injury and Single Embryo Transfer
Primary Infertility
Primary: Clinical Pregnancy Rate
N/A N=36 Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
Endometrial Carcinoma
Primary: Expression of Cell Cycle-related Proteins — 46.1; 0.8; 0.7 score on a scale — p=0.033
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Early Phase 1 N=50 Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Primary: Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) — 53.6; 42.7 units on a scale — p=0.87
Phase 2 N=32 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients Completing the Protocol — 27 Participants
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
N/A N=30 High Intensity Interval Training in Endometrial Cancer
Endometrial Cancer
Primary: Change in Proliferative Markers in Endometrium Before and After HIIT Exercises — 21.7; 15.1; 21.7; 20.2 Percentage of cells expressing Ki67
Phase 3 N=662 Endometrial Safety Study
Postmenopause
Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants
N/A N=54 Diet and Physical Activity in Uterine Cancer Survivors
Endometrial Neoplasms
Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants
Phase 2 N=35 RAD001 in Recurrent Endometrial Cancer Patients
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants
Phase 2 N=384 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Cell Carcinoma · Cervical Small Cell Carcinoma
Primary: The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Abdomen — 50; 65 percentage of participants
Phase 4 N=37 Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Endometriosis · Infertility
Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants